ZEPP vs. ALGS, MLSS, BLRX, DRIO, ICCM, RVPH, AMIX, RPHM, EQ, and BOLT
Should you be buying Zepp Health stock or one of its competitors? The main competitors of Zepp Health include Aligos Therapeutics (ALGS), Milestone Scientific (MLSS), BioLineRx (BLRX), DarioHealth (DRIO), IceCure Medical (ICCM), Reviva Pharmaceuticals (RVPH), Autonomix Medical (AMIX), Reneo Pharmaceuticals (RPHM), Equillium (EQ), and Bolt Biotherapeutics (BOLT). These companies are all part of the "medical" sector.
Zepp Health (NYSE:ZEPP) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, media sentiment, profitability, community ranking, dividends, valuation, institutional ownership and earnings.
Zepp Health has a net margin of -8.66% compared to Aligos Therapeutics' net margin of -783.72%. Zepp Health's return on equity of -8.55% beat Aligos Therapeutics' return on equity.
Zepp Health has higher revenue and earnings than Aligos Therapeutics. Zepp Health is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.
Zepp Health has a beta of 0.88, meaning that its share price is 12% less volatile than the S&P 500. Comparatively, Aligos Therapeutics has a beta of 2.37, meaning that its share price is 137% more volatile than the S&P 500.
Aligos Therapeutics received 21 more outperform votes than Zepp Health when rated by MarketBeat users. Likewise, 62.16% of users gave Aligos Therapeutics an outperform vote while only 40.00% of users gave Zepp Health an outperform vote.
Zepp Health presently has a consensus target price of $4.96, indicating a potential upside of 457.24%. Given Zepp Health's higher probable upside, equities analysts plainly believe Zepp Health is more favorable than Aligos Therapeutics.
In the previous week, Zepp Health had 3 more articles in the media than Aligos Therapeutics. MarketBeat recorded 6 mentions for Zepp Health and 3 mentions for Aligos Therapeutics. Aligos Therapeutics' average media sentiment score of 0.65 beat Zepp Health's score of 0.56 indicating that Aligos Therapeutics is being referred to more favorably in the news media.
52.6% of Zepp Health shares are held by institutional investors. Comparatively, 60.4% of Aligos Therapeutics shares are held by institutional investors. 36.0% of Zepp Health shares are held by insiders. Comparatively, 16.5% of Aligos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
Zepp Health beats Aligos Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Zepp Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZEPP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ZEPP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Zepp Health Competitors List
Related Companies and Tools
